Fluoroquinolone use restrictions in patients with uncomplicated infections and safety issues
n May 2016, US FDA advised to restrict fluoroquinolones use in patients with acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. The reason for this decision was the new safety data obtained during the pharmacovigilance in the USA – Fluoroquinolone...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2017-08-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2017/3/cmac-2017-t19-n3-p208/cmac-2017-t19-n3-p208.pdf |
| Summary: | n May 2016, US FDA advised to restrict fluoroquinolones use in patients with acute sinusitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. The reason for this decision was the new safety data obtained during the pharmacovigilance in the USA – Fluoroquinolone-Associated Disability (FQAD). This article discusses issues of fluoroquinolone safety and regulatory measures to prevent a risk for serious adverse drug reactions in the administration of this antibiotic class. A special attention is paid to FQAD and its clinical significance in terms of rational fluoroquinolone use. |
|---|---|
| ISSN: | 1684-4386 2686-9586 |